Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

Thorne SH, Liang W, Sampath P, Schmidt T, Sikorski R, Beilhack A, Contag CH.

Mol Ther. 2010 Sep;18(9):1698-705. doi: 10.1038/mt.2010.140.

2.

Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH.

Mol Ther. 2013 Mar;21(3):620-8. doi: 10.1038/mt.2012.257.

3.

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP.

Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095.

4.

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA.

Gene Ther. 2009 May;16(5):689-99. doi: 10.1038/gt.2009.29.

5.
6.

Oncolytic Immunotherapy for Treatment of Cancer.

Tsun A, Miao XN, Wang CM, Yu DC.

Adv Exp Med Biol. 2016;909:241-83. doi: 10.1007/978-94-017-7555-7_5. Review.

PMID:
27240460
7.

Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.

Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH.

Neoplasia. 2012 Dec;14(12):1115-21.

8.

Potentiating cancer immunotherapy using an oncolytic virus.

Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunellière J, Bramson JL, Lichty BD, Wan Y.

Mol Ther. 2010 Aug;18(8):1430-9. doi: 10.1038/mt.2010.98.

9.

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.

Rajani KR, Vile RG.

Viruses. 2015 Nov 13;7(11):5889-901. doi: 10.3390/v7112914. Review.

10.

Oncolytic HSV as a vector in cancer immunotherapy.

Li H, Zhang X.

Methods Mol Biol. 2010;651:279-90. doi: 10.1007/978-1-60761-786-0_16.

PMID:
20686972
11.

Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.

Thorne SH, Contag CH.

Gene Ther. 2008 May;15(10):753-8. doi: 10.1038/gt.2008.42. Review.

PMID:
18356814
12.

Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.

Shi S, Wang R, Chen Y, Song H, Chen L, Huang G.

PLoS One. 2013 Jun 14;8(6):e65757. doi: 10.1371/journal.pone.0065757.

13.

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO.

Gene Ther. 2006 Jul;13(13):1010-20.

PMID:
16525479
14.

pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.

Choi JW, Jung SJ, Kasala D, Hwang JK, Hu J, Bae YH, Yun CO.

J Control Release. 2015 May 10;205:134-43. doi: 10.1016/j.jconrel.2015.01.005.

15.

Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1.

Zhuang X, Zhang W, Chen Y, Han X, Li J, Zhang Y, Zhang Y, Zhang S, Liu B.

BMC Cancer. 2012 Nov 23;12:549. doi: 10.1186/1471-2407-12-549.

16.

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG.

Hum Gene Ther. 2010 Apr;21(4):439-50. doi: 10.1089/hum.2009.143.

17.

Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors.

Ahmed AU, Ulasov IV, Mercer RW, Lesniak MS.

Methods Mol Biol. 2012;797:97-109. doi: 10.1007/978-1-61779-340-0_8. Review.

PMID:
21948472
18.

The role of oncolytic virus immunotherapies to subvert cancer immune evasion.

Workenhe ST, Verschoor ML, Mossman KL.

Future Oncol. 2015;11(4):675-89. doi: 10.2217/fon.14.254. Review.

PMID:
25686121
19.

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ, Ferreira L, Bridle BW, Conrad DP, Tang VA, Diallo JS, Arulanandam R, Le Boeuf F, Garson K, Vanderhyden BC, Stojdl DF, Lichty BD, Atkins HL, Parato KA, Bell JC, Auer RC.

Mol Ther. 2012 Sep;20(9):1791-9. doi: 10.1038/mt.2012.128.

20.
Items per page

Supplemental Content

Support Center